Detection of
trisomy 21 and other aneuploidies by paralogous gene quantification.
We computed theoretical z scores based on a given CV value, probe number, and fetal fraction using the following formula: [mean copy number (test)--mean copy number (normal)]/SD of the normal sample, where the mean copy number of the test sample containing
trisomy 21 fetal DNA is 2 + fetal fraction.
The study sample had either an intermediate or a high background risk for
trisomy 21, largely based on maternal age.
Trisomy 21 was seen in 17(38.64%) of the total cases observed out of which 3,4,2,1,2,1,1 cases were seen in less than or equal to 1, 2-3, 4-5, 6-7, 8-9, 10-11, 12-13 years of age respectively and no patient was seen in age group of 14-15 years, Nance-Horan syndrome was observed in 12(27.27%) cases out of which 2,1,3,2,1,1 cases were seen in less than or equal to1, 2-3, 4-5, 6-7, 8-9 and12-13 years of age respectively, while no case was enrolled in age groups 10-11 and 14-15 years.
The incidence of
trisomy 21 conceptions increases with maternal age.[sup][5] Subsequently, maternal parity was established as an additional independent risk factor [sup][6] and genetic predisposition as third independent risk factor.[sup][7],[8] An increase risk for DS may be the result of an autosomal recessive gene mutation, particularly in the Middle East where the rate of consanguinity is increasing.[sup][9]
Although the detection rate of cfDNA for
trisomy 21 is higher than that of traditional screening, the detection rate of traditional screening is also quite high at lower cost.
The NPV of cfDNA in this study was 100% (95% confidence interval, 99.8%-100%) for both
trisomy 21 and trisomy 18.
In a study of about 1,900 low-risk women whose mean maternal age was 30 years, cfDNA testing detected all cases of
trisomy 21. The PPV for
trisomy 21 was 45.5% compared with 4.2% with standard screening (N.
After cell-free DNA analysis became clinically available in 2011, ACOG and SMFM recommended it for women at increased risk of fetal aneuploidy, including women 35 years or older, fetuses with ultrasonographic findings indicative of an increased risk of aneuploidy, women with a history of trisomy-affected offspring, a parent carrying a balanced robertsonian translocation with an increased risk of trisomy 13 or
trisomy 21, and women with positive first-trimester or second-trimester screening test results.
Down Syndrome Research's mission is to find ways to improve the lives of people born with
trisomy 21, the cause of Down syndrome.